Dexcom Inc Stock Fundamentals
| D1EX34 Stock | BRL 9.07 0.42 4.86% |
DexCom Inc fundamentals help investors to digest information that contributes to DexCom's financial success or failures. It also enables traders to predict the movement of DexCom Stock. The fundamental analysis module provides a way to measure DexCom's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DexCom stock.
DexCom |
DexCom Inc Company Operating Margin Analysis
DexCom's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current DexCom Operating Margin | 15.90 % |
Most of DexCom's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DexCom Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, DexCom Inc has an Operating Margin of 15.9%. This is 145.32% lower than that of the Healthcare sector and 125.09% lower than that of the Diagnostics & Research industry. The operating margin for all Brazil stocks is notably lower than that of the firm.
DexCom Inc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining DexCom's current stock value. Our valuation model uses many indicators to compare DexCom value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DexCom competition to find correlations between indicators driving DexCom's intrinsic value. More Info.DexCom Inc is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about 0.17 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for DexCom Inc is roughly 5.90 . Comparative valuation analysis is a catch-all model that can be used if you cannot value DexCom by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for DexCom's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.DexCom Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DexCom's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DexCom could also be used in its relative valuation, which is a method of valuing DexCom by comparing valuation metrics of similar companies.DexCom is currently under evaluation in operating margin category among its peers.
DexCom Fundamentals
| Return On Equity | 31.66 | |||
| Return On Asset | 5.37 | |||
| Profit Margin | 24.45 % | |||
| Operating Margin | 15.90 % | |||
| Current Valuation | 4.96 B | |||
| Shares Outstanding | 4.84 B | |||
| Price To Earning | 2.07 X | |||
| Price To Book | 2.97 X | |||
| Price To Sales | 129.36 X | |||
| Revenue | 2.17 B | |||
| Gross Profit | 1.28 B | |||
| EBITDA | 415.8 M | |||
| Net Income | 530.6 M | |||
| Cash And Equivalents | 2.58 B | |||
| Cash Per Share | 26.72 X | |||
| Total Debt | 1.89 B | |||
| Debt To Equity | 0.95 % | |||
| Current Ratio | 5.78 X | |||
| Book Value Per Share | 19.68 X | |||
| Cash Flow From Operations | 409 M | |||
| Earnings Per Share | 28.32 X | |||
| Number Of Employees | 5.5 K | |||
| Beta | 0.74 | |||
| Market Capitalization | 280.7 B | |||
| Z Score | 88.8 |
About DexCom Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DexCom Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DexCom using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DexCom Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California. DEXCOM INC operates under Diagnostics Research classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 5500 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in DexCom Stock
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.